Business Wire

GA-ICONEX

27.8.2024 19:11:27 CEST | Business Wire | Press release

Share
M2S Group Acquires Iconex Label Solutions Business

M2S Group, a Wynnchurch Capital L.P. portfolio company, and Iconex LLC (“Iconex”), an Atlas Holdings (“Atlas”) portfolio company, jointly announced today that M2S Group has acquired the label solutions business of Iconex (“Iconex Labels”). Iconex Labels is now part of the M2S Group platform, a leader in the material science and solutions industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827252986/en/

Paul Charapata will lead the combined business, and Iconex CEO Craig Gunckel has been named to the board of M2S Group. The receipt solutions division of Iconex remains an independent business owned by Atlas. Craig Gunckel will continue to lead the receipt solutions business as Chief Executive Officer. Terms of the transaction were not disclosed.

Atlas formed Iconex in 2016 to acquire the Interactive Printer Solutions Division of NCR Corporation. Headquartered in Duluth, Georgia, Iconex is the premier provider of innovative solutions that power commerce around the world. M2S Group, headquartered in Appleton, Wisconsin, is a leading material science and solutions company providing high-performance products in multiple industries. Iconex is M2S Group’s fourth business unit, joining Appvion, Nekoosa and Decorative Films.

“Combining Iconex with M2S Group provides additional high-performance variable print label solutions to our customers and expands our portfolio of proven technology,” said M2S Chief Executive Officer Paul Charapata. “This transaction fully aligns with our long-term growth and diversification objectives. We are excited to welcome the Iconex coworkers and customers to M2S Group and are looking forward to continued success.”

“In partnership with the Iconex Leadership Team, we transformed the company’s nascent label operations into one of North America’s largest and most respected label manufacturers. Under the leadership of CEO Craig Gunckel and CFO Ira Genser, Iconex has led the label solutions market through innovative product development, superior operating performance, ‘best-in-class’ customer service, and the seamless integration of several acquisitions,” said Michael Sher, Partner at Atlas Holdings. “Atlas wishes the Iconex Labels team continued success with M2S,” Sher added.

“Iconex Labels joining the M2S Group is an attractive opportunity to combine complementary businesses. Iconex Labels has grown significantly through a dedication to customers, focus on innovation, and commitment to our coworkers. I am extremely proud of all that Iconex has achieved to date and I am excited to support Paul as the labels business continues to flourish as part of the M2S Group,” said Craig Gunckel, Chief Executive Officer of Iconex. “I especially want to thank all of our coworkers for their hard work and dedication, which made Iconex into the market leader it is today.”

About M2S Group

M2S Group is a leading material science and solutions company providing high-performance products in multiple industries through its three business units: Appvion, Nekoosa and Decorative Films. M2S Group consists of over 700 team members and operates in the application tapes, carbonless sheets, architectural window films, direct thermal paper and films, extruded films, and specialty print media sectors. For more information, please visit m2sgroup.com.

About Iconex

Iconex is the world’s leading low-cost provider of paper receipt and highly differentiated variable print label solutions that transform business processes to drive profitability, productivity, customer satisfaction and sustainability. A tradition of innovation dating back to 1887 is woven into the fabric of Iconex’s identity beginning with the company’s invention of the paper receipt, which revolutionized business transactions. That spirit of innovation continues with the introduction of Iconex Sticky Media™, Sticky Media G2 and other patented innovations that are relied on by several of the world’s largest companies in food & beverage, retail, quick service restaurants, grocery, pharmacy, manufacturing and distribution and logistics to streamline operations, leading to an improved customer experience. For more information, please visit iconex.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240827252986/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye